Our periodic publications on vitiligo are now attracting attention from public, regulatory bodies, industry, advocacy groups, and the academic research community.
- ABC's Of Vitiligo (coming soon)
- Newly Diagnosed: First Steps (coming soon)
- Vitiligo Q&A is available now in Chinese, Croatian, English, Italian, Macedonian and Russian
- Understanding Vitiligo (coming soon)
- E-book "Vitiligo: What's new, What's true" is coming to Amazon Kindle store near you in May 2013
NEW! Sodium oxodihydroacridinylacetate for treatment of an active vitiligo. Abstract and Presentation at the EADV (24 May 2013)
Dermatologic Therapy Journal (December 2012) "Vitiligo: State Of The Art"
A global interest in therapies for neglected diseases is rising, but traditional biopharma research and development process is prohibitively expensive to justify cost of their development. Vitiligo is a multifactorial orphan disease that affects at minimum 35 million people worldwide, yet no therapeutic solutions exist. We describe a budget-minded pursuit of the new therapy development for vitiligo, which includes a multidiscipline collaboration and effective bridging between academic research, biobanking, and bioinformatics. We anticipate that the our “theoretically induced and empirically guided” discovery process will enable development of more leads, with a much greater probability of success and under tighter budgets compared with those of the biopharma company. Ultimately, the multidisciplinary approach described below facilitates the collaborative development of personalized treatments for different patient subpopulations in vitiligo and other neglected diseases.
- Multidisciplinary approach to R&D in vitiligo, a neglected skin disease Valle, Y., Lotti, T. M., Hercogova, J., Schwartz, R. A. and Korobko, I. V. (2012) Dermatologic Therapy, 25: S1–S9
- Classification of vitiligo: a challenging endeavor. Hercogová, J., Schwartz, R. A. and Lotti, T. M. (2012) Dermatologic Therapy, 25: S10–S16
- Review of current clinical studies of vitiligo treatments. Korobko, I. V. (2012) Dermatologic Therapy, 25: S17–S27
- Quality of life in vitiligo patients. Teovska Mitrevska, N., Eleftheriadou, V. and Guarneri, F. (2012) Dermatologic Therapy, 25: S28–S31
- Treatments of vitiligo: what's new at the horizon. Lotti, T. M., Hercogová, J., Schwartz, R. A., Tsampau, D., Korobko, I., Pietrzak, A., Mitrevska, N. T., Valle, Y. and Buggiani, G. (2012) Dermatologic Therapy, 25: S32–S40
- Metabolic syndrome in vitiligo. Pietrzak, A., Bartosińska, J., Hercogová, J., Lotti, T. M. and Chodorowska, G. (2012) Dermatologic Therapy, 25: S41–S43
- Vitiligo road map. Lee, B. W., Schwartz, R. A., Hercogová, J., Valle, Y. and Lotti, T. M. (2012) Dermatologic Therapy, 25: S44–S56
The following works and publications have been supported with grants from the VR Foundation:
- Valle Y., Couture P., Lotti T., Korobko I. Cloud Medical Research Management (MRM): a Bio-IT tool for correlative studies in dermatology. (Journal Link, pdf) Treat Strategies (Dermatol). 2011; 1(1): 82-86.
- Minashkin MM, Salnikova LE, Lomonosov KM, Korobko IV, Tatarenko AO
Possible contribution of GSTP1 and other xenobiotic metabolizing genes to vitiligo susceptibility (Abstract)
- Lotti T., Hercogova J., Turini D., Tognetti L., Barygina V., Valle Y. (Eds). Natural Antioxidants in General Medicine and in Dermatology. World Health Academy Publication House (Zurich, CH), 2011. (Amazon link)
- Zhou L., Li K., Shi Y.-L., Hamzavi I., Gao T.-W., Henderson M., Huggins R. H., Agbai O., Mahmoud B., Mi X., Lim H. W., Mi Q.-S. Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T-cells. Pigment Cell Melanoma Res. 2012; 25(5): 602-611 (Abstract)
- Babeshko O.A., Lomonosov K.M., Gilyadova N.I. Role of cytokine in vitiligo pathogenesis. Russ J Skin Sex Transm Dis. 2012, (3): 37-41.
- Lomonosov K.M., Mironov A.Yu., Kuznetsov O.V., Babeshko O.A. Virus participation in vitiligo pathogenesis. Russ J Skin Sex Transm Dis. 2012; (1): 40-42.
- Lomonosov K.M., Esipov D.S., Babeshko O.A., Tatarenko A.O. Oxidative stress in pathogenesis of vitiligo. (Journal Link) Russ J Skin Sex Transm Dis. 2011; (1): 68-70.
Periodic Research Reviews
I support the petition to designate June 25 as Vitiligo World Day and save millions of people worldwide from social isolation and persecution.
Is it possible to stop the progression of vitiligo?
Vitiligo is progressive in 73% of cases and regressive in 1.3%. We usually explain to the patients that progression depends on the modality of the disease spreading: l...
What causes vitiligo?
It remains unclear what causes damage to melanocytes and their subsequent total inactivation and/or disappearance in vitiligo skin. There are several theories; the mos...
How can I treat vitiligo?
Choosing a treatment for vitiligo can be difficult, sometimes overwhelming. In general, first-line therapy should be safe, effective, minimally invasive, and cost effi...
I have vitiligo: will my children have vitiligo, too?
Although most cases of vitiligo are sporadic, familial clustering is not uncommon, and up to 20% of patients report on the affected relatives. In whites, the lifetime ...